Navigation Links
Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Date:10/4/2007

Data Safety Monitoring Board Recommends Continuing Study

NEW YORK, Oct. 4 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today the completion of interim analysis of its Phase III pivotal clinical trial of Immtech's oral drug candidate, pafuramidine. An independent Data Safety Monitoring Board (DSMB) conducted the interim analysis and recommended that the trial should continue as planned. The trial is evaluating the safety and tolerability of pafuramidine, and comparing pafuramidine's efficacy to pentamidine, a non-oral drug, in treating Human African Tryanosomiasis (HAT), also know as African sleeping sickness.

African sleeping sickness is a fatal, vector-borne parasitic disease spread by tsetse flies that threatens approximately 60 million people in sub- Saharan Africa. Current treatments for the first stage of the disease include pentamidine and suramin. Both of these intravenous drugs are associated with reported toxic side effects. If approved, pafuramidine could become the first safe and effective oral treatment for first-stage African sleeping sickness.

Carol Olson, MD, PhD, Immtech's Sr. Vice President and Chief Medical Officer stated, "Successfully completing pafuramidine's Phase III interim analysis is a major milestone on the path to registering pafuramidine for treatment of African sleeping sickness. The next major milestone will be to have the remaining patients complete the 12-month follow up protocol and for Immtech to prepare the documents for the NDA submission. We aim to have pafuramidine approved to combat this devastating infectious disease."

Enrollment in this trial was completed earlier in 2007, and all patients are expected to complete
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... ALISO VIEJO, Calif. , Nov. 26, 2014 ... today announced that the U.S. Food and Drug ... to its New Drug Application (NDA) for AVP-825. ... of low-dose sumatriptan powder delivered intranasally utilizing a ... In the Complete Response letter, and consistent with ...
(Date:11/26/2014)... Scott Steiger lives in St. Louis ... for the past 20 years, he,s traveled extensively and prior to ... to six of the seven continents. Travel is a big part ... Photo - http://photos.prnewswire.com/prnh/20141126/161077 So when he ... idea of what,s required. His latest creation is the ...
(Date:11/26/2014)... 26, 2014 Zynerba Pharmaceuticals , Inc., ... innovative transdermal synthetic cannabinoid treatments, today announced that the ... Healthcare Conference 2014. The conference will be held December ... New York . Zynerba,s Chairman and ... pm on Tuesday, December 2. To listen ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... Dec. 9 BrainLAB, a manufacturer of software-driven ... St. Luke,s Hospital in Cedar Rapids, Iowa, has acquired ... Digital Lightbox© with TraumaCad(TM), a pre-operative planning and digital ... North America to acquire this technologically advanced duo. ...
... , INDIANAPOLIS, Dec. 9 tw telecom ... voice, Internet and data networking solutions for businesses in Indianapolis ... has selected the company to provide advanced voice, data and ... Indiana. Indiana Blood Center will also utilize tw telecom, ...
Cached Medicine Technology:St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows ... life, and she wants to lessen its impact. "After ... decided that there needed to be a way to ... to use and producible in design variations, the End ... areas throughout the day. It avoids bad odors, as ...
(Date:11/27/2014)... New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated litigation ... LLP reports. , Documents recently updated in ... records included in the state proceeding, all of ... bipolar disorder and other psychiatric conditions. Many of ...
(Date:11/27/2014)... WEDNESDAY, Nov. 26, 2014 (HealthDay News) -- Most babies ... a cold, the U.S. Food and Drug Administration says. ... be given to children younger than 2 because they ... agency warned. American adults average about three colds ... children get a cold, parents might want to give ...
(Date:11/27/2014)... (HealthDay News) -- Thanksgiving meals can pose a challenge ... an expert says. Many traditional Thanksgiving dishes -- ... -- are gluten-free, but "when it comes to pies, ... considered," Dr. Anca Safta, director of the Gluten and ... Center in North Carolina, said in a center news ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
... June 3 OrthoSynetics(TM), the largest,provider of business ... two new members to its IT team. Allen ... and David D,Entremont has,been hired as senior network ... facet of our organization, and,the addition of these ...
... be issued under second round of Critical Challenges ... The Michael J. Fox,Foundation for Parkinson,s Research ... test non-invasive imaging technologies that would allow,scientists to ... the living brain. Such techniques hold potential to,serve ...
... Public Relations, WALTHAM, Mass., June 3 ... relations agencies, today announced,that its co-founders, Steve and ... J. Malloy Crystal Bell Lifetime Achievement Award last ... Ringer Awards., (Logo: http://www.newscom.com/cgi-bin/prnh/20080603/NETU111 ), ...
... Growths are able to maintain significant testosterone ... June 3 (HealthDay News) -- U.S. researchers ... prostate cancer becomes resistant to androgen-deprivation therapy, ... promotes prostate cancer growth. , Androgen therapy, ...
... seen in those who had relatives with disease, study finds ... that increases the risk of developing colorectal cancer also seems ... study indicates. , People with colorectal cancer who had close ... die or to have a recurrence after treatment, according to ...
... at Cold Spring Harbor Laboratory (CSHL) have taken the ... a newly published paper, they confirm that a gene ... in living mice that its deletion, inactivation or loss ... cancer closely related to common human epithelial cancers of ...
Cached Medicine News:Health News:OrthoSynetics(TM) Adds Two Experienced Pros to IT Team 2Health News:Michael J. Fox Foundation for Parkinson's Research Commits up to $2 million to Visualize Alpha-Synuclein Protein in the Brain 2Health News:Michael J. Fox Foundation for Parkinson's Research Commits up to $2 million to Visualize Alpha-Synuclein Protein in the Brain 3Health News:Steve and Paula Mae Schwartz Honored With Publicity Club of New England's Crystal Bell Award 2Health News:Androgen Production Continues in Prostate Cancer Tumors 2Health News:Family History Might Improve Odds Against Colon Cancer 2Health News:CSHL scientists trace causal link between a tumor suppressor gene and liver cancer 2Health News:CSHL scientists trace causal link between a tumor suppressor gene and liver cancer 3
Shoulder rasp...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
85 left angled suture passer....
45 right angled suture passer....
Medicine Products: